En anesthesie, certains facteurs specifiques limitent I'interpretation des etudes portant sur Vefficacite, le rendement et la productivite de la technologic Certains de ces problemes sont passes en revue, en particulier I'absence de resultats specifiques necessitant I'utilisation de mesures intermediates (par ex., I'hypoxemie, I'ischemie myocardique) qui ne sont pas en rapport direct avec le devenir ultime des patients. Ceci souligne pour I'anesthesie le besoin de chercheurs orientes vers la definition des problemes fondamentaux et I'elaboration subsequente d'etudes appropriees. Au regard des moniteurs, le delai de reaction (ou la rapidite de I'alarme produite) d'un moniteur compare au temps requis pour modifier efficacement un traitement doit etre mieux defini et compare au delai de reaction enregistre sans moniteur. Apres avoir defini le bienfait d'un moniteur, les chercheurs doivent en analyser le cout relatif avec ses alternatives (cout-benefice et cout-efficacite). Un modele hierarchique servant a guider revaluation de la technologie est presente dans I'ordre suivant: la base scientifique de la technologie et son importance sur le patient suivies par des problemes societaux. Traditionnellement, les anesthesistes ont eu recours aux methodes devaluation technologique adoptees par d'autres disciplines. Cette methodologie ne s'adresse pas aux problemes specifiques a la discipline d'anesthesie (comme le delai de reaction). En definissant les problemes specifiques a I'anesthesie, ilfaut developper des nouvelles mesures de resultats qui mettront I'accent sur les facteurs humains qui influencent la prise de decision en salle d'operation. A I'avenir, les evaluations de la technologie necessiteront des approches innovatrices qui s'adresseront aux problemes specifiques a I'anesthesie. Une telle approche comprend I'utilisation de la simulation des types de reponses aux incidents graves.
of new intraoperative monitoring devices. While some monitors, such as pulse oximeters, have relatively low unit costs, equipping all operating rooms, postanaesthesia care units and even wards with this technology results in a large expense. The anaesthetist-in-chief at a hospital must determine priorities based on fixed budgets. Can the department afford both the latest technological advance and promising new drug(s)? Anaesthetists are increasingly expected to show justification and costeffectiveness before the acquisition of newer technologies. '
Terminology
While technology assessment can refer to any procedure, drug, device or process of care (preventive, diagnostic, rehabilitative), what is of particular interest among anaesthetists is the newer intraoperative monitors, which will be the main focus of this paper.
Technology assessment has been defined as the process of designing and conducting investigations which enable a reasoned judgment regarding the efficacy, the effectiveness and the efficiency of a monitor. 2 Efficacy has been referred to as the probability of benefit to individuals from the use of technology applied to a given medical problem under ideal conditions of use. 3 The key terms in this definition are "benefit to individuals" and "ideal conditions of use." Efficacy studies are generally carried out at tertiary care hospitals, by academic physicians, with strict protocols, and using a set of narrow inclusion criteria to a well-defined group of patients, say white men aged 50-65 yr. The study patients (who may not be representative of all patients with the condition) are carefully monitored by trained designated research staff and compliance is usually ensured by careful follow-up of patients.
In contrast, effectiveness refers to patient benefit among the general population, when the technology is used in routine, clinical practice by clinicians who are not academic or in large centres. While an efficacy study of a particular technology may show a positive benefit among a select group of patients, when used by communitybased physicians on a wider group of patients, for example, women aged >65 yr, there may not be a benefit. There may be a variety of reasons to account for the differing results. The technology may only be of benefit to younger men perhaps due to physiological differences between men and women. The technology may not have been used or interpreted in a proper fashion; the settings may be incorrectly calibrated or the machine may not have been maintained regularly. The indications for the technology may be different from or widened from the efficacy studies or may not be applicable to the new indication. Alternatively, compliance with the technology may be poor as there is no systematic follow-up to its use (e.g., used for some patients but not others in a haphazard fashion.) Appropriate applications of a new technology in widespread practice may be delayed if practitioners do not receive feedback from efficacy studies on earlier prototypes. Thus, any new technology must be assessed in the real world situation, as well as at academic centres, to determine if there is any true net benefit to individuals for general medical use.
Outcome assessment
Most clinical anaesthetists intuitively believe that monitors have contributed to a reduction of perioperative morbidity and mortality. Yet proving this clinical impression with traditional techniques of epidemiological and scientific investigation has been difficult. 4 -5 For example, with reference to the improvement in patient outcome attributable to pulse oximeters, Orkin demonstrated that the decrease in anaesthesia-related mortality began decades before the advent of these monitors 6 with most of the decline occurring before their introduction. Nonetheless, studies have attempted to evaluate monitors by using ingenious methodologies, for example, using the pulse oximeter but not telling the anaesthetist unless there was a problem. 7 Two fundamental problems have been recognized in the conduct and design of studies to evaluate monitors. The first problem relates to the absence of a specific measurable outcome for monitor-related problems as a result of a lack of a clear definition of the clinical issue studied. This emphasizes a need for investigators of anaesthesia technology to define clearly the fundamental issue studied and to design the intervention to address this clinical problem specifically. Some examples will help to illustrate this point.
Consider death from anaesthesia as the main outcome measure of an assessment of a new technology. One would think that this is relatively straightforward, as deaths are easy to count. However, there are a number of problems. First, the definition of death is more complex than it used to be (e.g., by death do we mean brain death?). Secondly, how much later, after the surgical procedure, would a death be convincingly attributable to what the anaesthetist has done in the operating room? Third, what is the definition of anaesthetic-related mortality? 8 In the 1990s, there are so many other factors contributing to mortality that the anaesthetic component is extremely difficult to evaluate clearly. 9 -10 Even if these considerations could be sorted out to everyone's satisfaction, there is still an obstacle in that death attributable to anaesthesia is extremely rare. Studies would be hopelessly complicated by the large patient groups required. For example, to detect a 20% improvement in anaesthesia mortality (a current estimate is 0.056 per 10,000 anaes-thetics),'' one would require more than 250,000 patients to show an effect of preventative technology. Even if one could show this effect, while the relative improvement may be interesting, the absolute difference is clinically meaningless. Such studies will not likely be completed.
The second problem relates to the use of intermediate outcomes which others have suggested be used instead of major outcomes such as death. Intermediate outcomes include hypoxaemia, ischaemia, and so forth, and have several advantages in that they can be clearly defined, occur more frequently, and can be more directly attributable in time to what the anaesthetist does. However, the use of intermediate outcomes is also problematic. There are two interrelated concerns about the use of intermediate outcomes. First, the relationship between intermediate outcomes and true outcomes (e.g., major morbidity and death) is not necessarily a direct or linear relationship. There may be many false alarms where the actual physiological value of the measurement falls below the threshold value, but the patient is not really in any danger. After all, we do not know what the age and sex-specific normal values are for pulse oximetry. There may be many individuals walking around with clearly abnormal values. The second relates to "lead time" or early warning provided by the monitor compared with that in routine clinical practice without the monitor or with alternative techniques. 4 The clinical importance of detecting a physiological event depends upon whether early detection results in the opportunity to apply a therapy early enough to be effective. If earlier detection using a monitor results in only a very brief increase in the early warning system and the clinician cannot institute effective therapy within this timeframe, the lead time of the monitor cannot be expected to effect an improved outcome. As well, if there is no therapy available to influence outcome, then the patient will not benefit even if the monitor does detect the physiological abnormality well in advance. In this circumstance, as in very brief lead time, there is no advantage in having the monitor (i.e., no benefit to patients). The challenge to the investigator is to determine how to demonstrate a benefit and then estimate the cost relative to any monitoring alternatives (cost-benefit or cost-effectiveness).
Pulse oximetry
If surveyed, most anaesthetists would agree that pulse oximetry has improved patient outcome. The Canadian Anaesthetists' Society (among others) has adopted guidelines l2 that mandated the routine use of oximetry without evidence from randomized clinical trials. Most anaesthetists believed then, and continue to believe, that oximetry prevents hypoxic injuries.
In 1993, Moller et al from Denmark, 13 ' 14 conducted what is likely to be the only large randomized evaluation of pulse oximetry in which over 20,000 patients were followed. Importantly, these investigators focused on the relationship between the detection of intraoperative and post-anaesthesia care unit (PACU) events by oximetry and postoperative complications. As expected, the incidence of intermediate outcomes such as respiratory events, including desaturation, was greater in the oximetry-monitored group than in the control (nonoximetry monitored) group. Yet, postoperative complications, such as pneumonia, atelectasis, myocardial infarction, were not different. Does this imply that pulse oximetry is not effective? The answer is that this study can neither confirm nor deny the effectiveness of pulse oximetry. Due to the relatively small sample size and other methodological concerns, one cannot rule out that pulse oximetry may be effective.
Technology assessment
We may have reached the point in the assessment of monitoring technology in anaesthesia where traditional approaches, such as the randomized controlled trial (RCT), useful as they have been, are too restrictive. Other techniques of technology assessment such as literature reviews, meta-analysis, consensus panels, cost-effectiveness analyses, database registries have been used in internal medicine, critical care and radiology to assess technology. Some of these techniques may also be applicable to anaesthesia. However, in anaesthesia, it appears that we need to adopt techniques that specifically address the issue of the warning function of our monitors. These studies should focus on the human factor, how we respond to warnings and the lead time factor. We need to define problems specific to the specialty of anaesthesia objectively and develop innovative outcome measures related to these problems. An outline, or template, for technology assessment has been developed and used by radiologists l5 and this may be useful for the evaluation of anaesthesia technology. There are some similarities to the use of screening radiology such as mammograms and the use of anaesthesia monitors in that both serve an early warning function. Both have a technical component related to the measurement aspect of the technology. For example, the radiogram must be calibrated for exact penetration of the x-ray beam to maximize the image and minimize the "background," whereas the anaesthesia monitor must be set to maximize true physiological deviations and minimize false alarms.
The template proposed by Fryback and Thornbury 15 can be used to classify assessment studies. The model goes beyond the usual goal of providing "the best images and the best diagnosis" in radiology to be part of a larger system, aimed at treating patients effectively and efficiently. The template is a "hierarchical model" as it addresses the scientific basis of the technology itself, then the influence on the patient, followed by societal issues. For a monitor to be efficacious at a higher level, it must be efficacious at a lower level, but not necessarily vice versa. We have modified this template for the potential assessment of anaesthesia technology as follows:
Basic science of the technology Anaesthetists have been among medicine's most conscientious investigators in understanding the fundamental principles of applied monitoring technology. At this stage, a monitor is conceived, the prototypes developed, and the patents obtained. This is followed by an assessment of the technical aspects including the physical characteristics of the monitor, its ability to measure physiological variables, the various adjustments and sensitivities required for the technical functioning of the monitor. This assessment permits comparison with other techniques based on these characteristics. This assessment is usually carried out in the laboratory, often using animal models. However, while a monitor may be useful in a research laboratory, one cannot assume that it will be of ultimate benefit to patients in the clinical setting.
Site I indications for use
In anaesthesia practice, specific indications for monitoring have been rigorously identified in clinical trials for the use of some monitors. However, in practice, we have often extended the use of these monitors to other circumstances and other locations (e.g., pulse oximetry was developed for the operating room but now is used in the PACU and on the ward) without documented effectiveness of its use in these settings, a so-called "technology creep." 16 Thus, both the proposed site and the specific indications for use need to be rigorously delineated.
Efficacy
Fryback and Thornbury 15 discussed six levels of efficacy:
1 TECHNICAL EFFICACY A monitor must be able to measure physiological variables in a reliable fashion under ideal conditions in clinical practice.
DIAGNOSTIC EFFICACY
This can be defined in various ways such as the number of abnormalities found, or predictive values such as sensitivity and specificity. However, as in other disciplines, establishing the "gold standard" for comparison is often not readily clear. This needs to be done in clinical practice under the actual circumstances of use. Thus, the characteristics of the monitor in practice that are not evaluated in the developmental phase can be assessed. For example, diagnostic efficacy of a monitor may be reduced in the operating room because of electromagnetic interference, which may not have been detected during development. We cannot assume that monitors will be used optimally in clinical practice, that the device will be properly applied, or that the information will be optimally interpreted in a timely manner. Even at this stage, one cannot assume that there will be benefit to patients.
3/4 DIAGNOSTIC THINKING EFFICACY AND THERAPEUTIC

EFFICACY
These concepts are closely related so they will be discussed together. Diagnostic thinking efficacy refers to the change in the clinician's thought processes because of the information provided by the monitor. Therapeutic efficacy, on the other hand, refers to the impact of the information on implementing effective therapy. Patients' outcomes cannot be affected unless the anaesthetist is willing to act differently based on the information provided by the monitor. The information provided may provoke the anaesthetist to change a specific drug, delay extubation, or merely to continue on the present course (be reassured that the patient is not in danger). To illustrate this, a less celebrated outcome of the Danish pulse oximetry study 14 was that although there were no measurable differences in patient outcomes, anaesthetists in the study felt more reassured by having pulse oximeters. This "thinking and acting" process that anaesthetists use can be assessed methodologically for example by using patient scenarios in questionnaires. However, what anaesthetists say they would do is not necessarily what they actually do. Even what they actually do may not affect the ultimate patient outcome, so that again, patient benefit cannot be assessed at this level. 5 PATIENT OUTCOME As noted above, the ultimate aim of anaesthesia care is benefit to the patient so that the determination of appropriate outcome measures is critical. It has been argued that the field of anaesthesia needs to broaden its concept of what is an outcome measure.
Anaesthetists are familiar with mortality or major morbidity as true endpoints and hypoxaemia, hypotension, hypothermia as intermediate outcomes. However, returning to the theme of "benefit to patients," newer concepts of outcome measures need to be considered. These include quality of life, psychological well-being, and time to return to usual activities. 4 ' 17 Expansion of the "traditional" anaesthesia research methods is also needed to include cost-effectiveness, decision analysis, and patient preferences.
SOCIETAL EFFICACY
Sometimes there is a conflict between what is the "best for the patient" and what society is willing to pay. Here, resources allocated to anaesthesia care will have to compete not only with other medical or surgical specialties, but also with non-medical factors contributing to health of the population including recreation, roads, and the arts. 18 Thus, the introduction of new technology must be seen to be cost-effective not only in comparison with other competing technologies which purport to prevent the same disorders but also in relation to preventing or treating other non-related disorders. New, more costeffective monitors may replace existing technologies, but unless the old technology is abandoned, newer technologies could be considered as "add-ons."
Effectiveness
The study of the use of medical technology in the every day world is known as "outcomes research." Outcomes research has been defined as "linking the type of care received by a variety of patients with a particular condition to positive and negative outcomes in order to identify what works best for which patients." 19 Guadagnoli and McNeil l9 suggest that there are a variety of factors which have led to a marked interest in this research. These include the costs of care, the need to make decisions about resource allocation, and the need to assess quality of care. While we are seeing more outcomes research in the field of anaesthesia, these studies are still rare.
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The future
The need for a rigorous scientific approach to technology assessment of anaesthesia monitors is clear. Innovative devices continue to be developed and traditional approaches to the assessment of monitors that clinicians intuitively believe are effective have been inadequate and narrowly focused. Anaesthetists must develop innovative techniques of assessment that specifically address problems related to anaesthesia outcome. We have learned that outcome measures used in internal medicine, surgery and radiology are good starting points, but are not specific enough for our needs. For example, clinical decision analyses often use utilities to measure quality of life in such ways as quality-adjusted life expectancy (QALE) or quality-adjusted life years (QALY) so that alternate therapies can be directly compared to one another. The conceptual framework behind such "endpoints" are years of life spent in various "health states" which range from perfect health, physical disability, pain, discomfort, emotional problems, social dysfunction, and so forth. 21 Since anaesthesia does not directly "treat" diseases, these concepts have limited applicability to the discipline of anaesthesia. Nonetheless, the development of a "single" quality endpoint for anaesthesia will be worthwhile so that the costeffectiveness of various drugs, monitors, and techniques can be more easily compared.
Another area where research is needed is to address the "warning function" of monitors. Examples of innovations that may be useful in addressing this issue are simulation technology and prioritized monitoring alarms. Both of these techniques address issues related to the warning function. Simulation-based learning may help us understand how clinicians respond to warning signals and change treatment strategies when confronted with additional information. Experience with simulation-based research methods may assist in better defining the "lead time" required to effect changes in therapy. 22 Prioritized alarms may aid in establishing a sequential response pattern and minimize information overload from the cacophony of competing monitoring alarm systems. 6 Of course, these systems would need to be evaluated before widespread adoption.
Conclusion
Unless clinical investigators become more innovative and focus on specific anaesthesia problems, it will be difficult, if not impossible, to demonstrate improved patient outcome from our monitors. Without this supportive information, anaesthetists will be at a disadvantage when resource allocation decisions are made. It is essential that our investigators be trained in clinical epidemiology, the decision sciences, and biostatistics as well as clinical anaesthesia, to address creatively specific problems related to anaesthesia practice.
